Skip to main content
Clinical Trials/NCT02626871
NCT02626871CompletedNot Applicable

Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation

University of Turku1 site in 1 country850 target enrollmentStarted: January 2002Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
850
Locations
1
Primary Endpoint
Mortality

Study Overview

Brief Summary

The primary purpose of the FIN-bioAVR registry is to assess the incidence of AF, strokes and major bleeding events in patients undergoing aortic valve replacement. This retrospective multicenter registry will include 850 patients with aortic valve replacement using bioprosthesis.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 99 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • patients undergoing aortic valve bioprosthesis implantation

Exclusion Criteria

  • mechanical heart valves in any position

Outcomes

Primary Outcomes

Mortality

Time Frame: 10 years

atrial fibrillation

Time Frame: 10 years

major bleeding

Time Frame: 10 years

Stroke

Time Frame: 10 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Tuomas Kiviniemi

MD, PhD

University of Turku

Study Sites (1)

Loading locations...

Similar Trials